LSLeila Smati

Leila Smati

*This is an algorithmically generated author record based on publicly available information.

Leila Smati has a total of 92 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    MHC class II deficiency in Algeria: Delineating the clinical, immunological, and genetic spectrum

    by Azzeddine Tahiat, Lorenzo Cuollo, Sofija Buta Panov, Saliha Hakem, Souad Touri, Amina Saad-Djaballah, Chafa Bendahmane, Abdelbassat Ketfi, Abdelghani Yagoubi, Reda Belbouab, et al.

    MHC class II deficiency is the most frequent combined immunodeficiency (CID) in the Maghreb, yet its phenotypic and molecular spectrum remains incompletely defined. Herein, we characterized 46 Algerian patients at the clinical, immunologic, and molecular levels. Disease onset was typically early, with a median age of 4.5 mo, while the clinical course was highly heterogeneous, ranging from severe, rapidly progressive disease to milder phenotypes with survival into adulthood. Recurrent infections were a universal feature, with protracted diarrhea (80.4%), recurrent pneumonia (71.7%), and oral candidiasis (54.3%) being the most common manifestations. CD4 lymphopenia occurred in 87% of patients, although lymphocyte profiles ranged from near-normal to SCID-like. Absent or nearly absent HLA-DR expression on both B cells and monocytes was observed in 44 patients, while two exhibited residual HLA-DR expression on B cells. Among 35 genetically characterized patients, 30 (85.7%) carried the recurrent RFXANK c.338-25_338del26 founder variant, while additional variants in RFXANK, RFXAP, and CIITA further broadened the molecular spectrum.

  • Open Access

    MHC-II deficiency in a large Algerian cohort: Clinical, immunological, and genetic characterization

    by Lydia Lamara Mahammed, Brahim Belaid, Koon-Wing Chan, Aida Mohand-Oussaid, Ouardia Drali, Abdelhak Dehimi, Daniel Leung, Lilya Meriem Berkani, Hassiba Sakhri, Asmaa Abed, et al.

    MHC class II (MHC-II) deficiency is a rare inborn error of immunity caused by defects in transcriptional regulators of MHC-II expression. In this study, we characterized the clinical, immunological, and molecular features of 107 patients from 98 unrelated Algerian families. Median ages at symptom onset and diagnosis were 5 and 14 mo, respectively, with pneumonia (82%) and chronic diarrhea (73%) predominating. CD4+ T cell lymphopenia occurred in 87.6% and naïve CD4+ T cell depletion in 86.0%. Among 99 genetically characterized patients, variants were identified exclusively in RFXANK (77.8%) and RFXAP (22.2%), including two predominant mutations (RFXANK c.338-25_338del and RFXAP c.368del) and four novel variants. Exploratory comparisons suggested a more severe phenotype in patients carrying RFXAP c.368del than in those carrying RFXANK c.338-25_338del. Five of seven transplanted patients survived versus 33.3% of non-transplanted patients. As the largest MHC-II deficiency cohort reported to date, this study substantially expands current knowledge of the disease and supports targeted genetic diagnosis in North African populations.

  • Open Access

    The genetic landscape of RAG deficiency: Novel and founder variants in a large Algerian cohort

    by Brahim Belaid, Koon-Wing Chan, Jennifer Stoddard, Julie Niemela, Heather Kenney, Adriana A. De Jesus, Daniel Leung, Jing Yang, Xing Tian Yang, Abdelhak Dehimi, et al.

    RAG1/RAG2 deficiency causes diverse SCID phenotypes, but large, systematically characterized cohorts from North Africa remain lacking. We retrospectively characterized 128 confirmed RAG1/RAG2-deficient patients diagnosed over 14 years in Algeria, classified per PIDTC 2022 criteria. Consanguinity was high (70.3%), with RAG2 (57.0%) outnumbering RAG1 (43.0%), a reversal of patterns reported elsewhere. Classical SCID (61.0%) and Omenn syndrome (23.4%) predominated. Two candidate founder variants (RAG1 c.519del, RAG2 c.104G>T) accounted for 76.6% of genotypes, yet identical c.519del genotypes produced three discordant phenotypes. Four novel variants and four digenic/oligogenic cases broadened the molecular spectrum. Despite a short diagnostic delay, mortality was 89.1%, driven primarily by near-absent HSCT access (2.3%). This study expands the molecular and clinical spectrum of RAG deficiency in an underrepresented population, revealing a reversed RAG1/RAG2 ratio and phenotypic heterogeneity despite shared founder genotypes. These findings prioritize functional validation of uncertain-significance variants and underscore the need for NBS and expanded transplant access to translate diagnosis into survival.